FDA Approves Lytenava for Wet AMD on Fourth Attempt

The FDA approved Lytenava (bevacizumab-vikg) on July 24, 2026, for neovascular (wet) age-related macular degeneration. Outlook Therapeutics (OTLK) finally succeeded on its fourth BLA resubmission after three prior complete response letters. The approval came five days ahead of the July 29 PDUFA date.

Price update August 2, 2026 (Polygon): OTLK closed at $0.98 on July 31, down from $1.04 on July 30. The stock has stabilized just below $1.00 after the initial post-approval sell-off from the $1.32 approval-day reference price. Market cap is approximately ~$185 million. The analysis below remains unchanged.

Lytenava is the first and only FDA-approved ophthalmic formulation of bevacizumab. Ophthalmologists have used off-label compounded bevacizumab for wet AMD injections for over a decade, but those preparations lack standardized manufacturing, FDA-approved labeling, and pharmacovigilance. Lytenava changes that.

The four-attempt regulatory saga

Outlook Therapeutics received three prior CRLs from the FDA. The company had to win a formal dispute resolution appeal to get this fourth resubmission accepted. The FDA concluded that substantial evidence of effectiveness had been established, clearing the path for resubmission and now approval.

The perseverance is notable. Most companies walk away after two CRLs. Outlook kept going, and the dispute resolution process worked. The stock closed at $1.32 on July 24 with 6.1 million shares traded, suggesting the market had been pricing in significant approval risk.

Why an approved bevacizumab matters

Bevacizumab (Avastin) was originally approved as a cancer drug. Retina specialists began using it off-label for wet AMD because it costs roughly $50 per dose, compared to $1,000-plus for Regeneron’s Eylea or Genentech’s Lucentis. Compounding pharmacies prepare the intraocular injection from vials meant for IV cancer treatment.

That works, but compounding introduces variability. An FDA-approved ophthalmic formulation gives physicians a standardized product with consistent dosing, proper labeling, and manufacturer pharmacovigilance. If payers prefer an approved bevacizumab over expensive branded anti-VEGF agents, Lytenava could capture meaningful share.

The wet AMD market is dominated by Regeneron’s Eylea franchise and Genentech’s Lucentis, both multibillion-dollar products. Lytenava enters at a lower cost point, but the question is whether payers will require its use before reimbursing pricier alternatives.

For more on how FDA approval decisions work, see our guide to PDUFA dates.

The commercial challenge

Outlook is a micro-cap company with a market capitalization of approximately $247 million. Lytenava is already approved in Europe, with launches underway in Germany, Austria, and the UK. The US launch will be the real test.

Can a company this size compete against Regeneron and Roche in retina specialist offices? The off-label use of compounded bevacizumab is already widespread, so Lytenava is competing against both branded products and a free compounded alternative. The value proposition depends on payer behavior. If insurers mandate FDA-approved bevacizumab before covering Eylea or Vabysmo, Outlook wins. If not, the compounded version remains the default low-cost option.

What to watch next

1. Pricing and reimbursement: Outlook has not disclosed the US list price. If it prices far below Eylea but above compounded bevacizumab, payers could steer volume toward it.
2. Launch execution: Outlook needs to build commercial reach into retina practices. Partnership or distribution deals could accelerate this.
3. Market reaction: The stock closed at $1.32 on approval day. Whether that reflects pre-approval pricing or post-approval valuation will become clearer in coming sessions.

Outlook Therapeutics closed at $1.32 on July 24, 2026, with a market cap of approximately $247 million.

Source: Outlook Therapeutics press release | FDA novel drug approvals